extract: 2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction
Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>
This commit is contained in:
Teleo Agents
parent
af067944f1
commit
08a6486f0e
6 changed files with 74 additions and 1 deletions
|
|
@ -53,6 +53,12 @@ The BALANCE Model directly addresses the chronic use inflation problem by requir
|
|||
|
||||
At net prices with 48% rebates, semaglutide achieves $32,219/QALY ICER, making it highly cost-effective. The Trump Medicare deal at $245/month (82% discount) would push ICER below $30K/QALY. The inflationary claim may need scope qualification: GLP-1s are inflationary at list prices but potentially cost-saving at negotiated net prices, and the price trajectory is declining faster than the 2035 projection anticipated.
|
||||
|
||||
|
||||
### Additional Evidence (challenge)
|
||||
*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-16*
|
||||
|
||||
Aon data shows that for long-term risk-bearers with adherent populations, GLP-1s become cost-saving after 12-18 months. Medical cost growth drops from 23% above baseline in year 1 to 2% in year 2+, with adherent diabetes patients showing 9 percentage points lower cost growth at 30 months. This suggests the 'inflationary through 2035' claim may be true for the aggregate healthcare system (dominated by short-term payers) but false for capitated systems that capture multi-year savings.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -47,6 +47,12 @@ This data comes from commercially insured populations (younger, fewer comorbidit
|
|||
|
||||
No data yet on whether payment model affects persistence—does being in an MA plan with care coordination improve adherence vs. fee-for-service? This is directly relevant to value-based care design.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-16*
|
||||
|
||||
Aon data shows that adherence is the binding variable for cost-effectiveness: the 80%+ adherent cohort shows medical cost growth 9 percentage points lower at 30 months for diabetes and 7 points lower at 18 months for weight loss, versus 6 and 3 points respectively for the full cohort. This means low persistence doesn't just reduce clinical benefits—it eliminates the economic case entirely by preventing the year 2+ cost savings from materializing.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -37,6 +37,12 @@ At $245/month list price, even modest copays ($50-100/month) create a sustained
|
|||
|
||||
The source does not provide granular income-stratified discontinuation rates, so the magnitude of the effect is unclear. It's possible income is a proxy for other factors (health literacy, access to care coordination, baseline health status) rather than affordability per se.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-16*
|
||||
|
||||
Aon's employer claims data (which skews toward employed, insured populations) shows strong adherence effects on outcomes, but the study notes that benefits scale dramatically with adherence. This suggests that populations with affordability barriers (not well-represented in employer claims) would see even weaker cost-effectiveness, reinforcing that economic access determines clinical and economic outcomes.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -40,6 +40,12 @@ FLOW trial (N=3,533, median 3.4 years follow-up) showed 24% reduction in major k
|
|||
|
||||
SELECT trial economic model shows $2,074 per-subject lifetime savings from avoided CKD, supporting the claim that kidney protection generates substantial cost savings. However, diabetes prevention ($14,431) generates even larger savings.
|
||||
|
||||
|
||||
### Additional Evidence (confirm)
|
||||
*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-16*
|
||||
|
||||
Aon's real-world data confirms multi-organ protection: adherent GLP-1 users show 47% reduction in MACE hospitalizations for women and 26% for men, plus associations with lower rates of osteoporosis, rheumatoid arthritis, and pancreatic disorders. The compounding value across organ systems is visible in the cost trajectory—medical cost growth drops from 23% above baseline in year 1 to 2% in year 2+ as multiple downstream complications are averted.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -0,0 +1,32 @@
|
|||
{
|
||||
"rejected_claims": [
|
||||
{
|
||||
"filename": "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
{
|
||||
"filename": "glp-1-receptor-agonists-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction-in-women.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
}
|
||||
],
|
||||
"validation_stats": {
|
||||
"total": 2,
|
||||
"kept": 0,
|
||||
"fixed": 2,
|
||||
"rejected": 2,
|
||||
"fixes_applied": [
|
||||
"glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md:set_created:2026-03-16",
|
||||
"glp-1-receptor-agonists-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction-in-women.md:set_created:2026-03-16"
|
||||
],
|
||||
"rejections": [
|
||||
"glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md:missing_attribution_extractor",
|
||||
"glp-1-receptor-agonists-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction-in-women.md:missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
"model": "anthropic/claude-sonnet-4.5",
|
||||
"date": "2026-03-16"
|
||||
}
|
||||
|
|
@ -7,9 +7,13 @@ date: 2026-01-13
|
|||
domain: health
|
||||
secondary_domains: [internet-finance]
|
||||
format: report
|
||||
status: unprocessed
|
||||
status: enrichment
|
||||
priority: high
|
||||
tags: [glp-1, employer-costs, cancer-risk, cardiovascular, cost-offset, real-world-evidence]
|
||||
processed_by: vida
|
||||
processed_date: 2026-03-16
|
||||
enrichments_applied: ["glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Content
|
||||
|
|
@ -49,3 +53,16 @@ WHY ARCHIVED: The temporal cost dynamics (costs up Y1, down Y2+) are the most im
|
|||
EXTRACTION HINT: Focus on the temporal cost curve and what it implies for different payment models. The cancer finding is separately important but preliminary.
|
||||
|
||||
flagged_for_rio: ["GLP-1 cost dynamics have direct implications for health investment thesis — long-term risk-bearers capture savings that short-term payers miss"]
|
||||
|
||||
|
||||
## Key Facts
|
||||
- Aon analyzed commercial health claims data from 192,000+ GLP-1 users in a multi-year study released January 13, 2026
|
||||
- First 12 months on Wegovy/Zepbound: medical costs rise 23% vs. 10% for non-users
|
||||
- After 12 months: medical costs grow 2% vs. 6% for non-users
|
||||
- For diabetes indication: medical cost growth 6 percentage points lower at 30 months; 9 points lower with 80%+ adherence
|
||||
- For weight loss indication: cost growth 3 points lower at 18 months; 7 points lower with consistent use
|
||||
- Female GLP-1 users: ~50% lower incidence of ovarian cancer
|
||||
- Female GLP-1 users: 14% lower incidence of breast cancer
|
||||
- Female MACE reduction: 47%
|
||||
- Male MACE reduction: 26%
|
||||
- Aon is a major insurance broker/consultant analyzing employer-sponsored commercial claims data
|
||||
|
|
|
|||
Loading…
Reference in a new issue